Truist Sees Major Upside in Terns Pharmaceuticals Stock
Truist initiates Terns Pharmaceuticals with Buy rating and $20 target, citing promising blood cancer drug and oral GLP-1 treatment potential.
/ 2 items
Truist initiates Terns Pharmaceuticals with Buy rating and $20 target, citing promising blood cancer drug and oral GLP-1 treatment potential.
Pharma giant Roche bought 89bio for up to $3.5B. The focus is pegozafermin, a promising drug for treating MASH (severe fatty liver disease). This deal positions Roche to transform care in metabolic diseases. Shares of 89bio surged 85% on Thursday.